immunosuppressive
[대역어] 면역억제제
[용어속성] Term
[용어속성] Term
Kidney Transplantation and COVID-19: Two Case Reports
신장 이식과 COVID-19: 2건의 사례 보고
Case Reports
[키워드] Azithromycin
Blood level
Comorbidities
coronavirus disease
Coronavirus disease 2019
Course
COVID-19
COVID-19 pneumonia
decreased mortality
diagnosis of COVID-19
died
dosage
dose
Favipiravir
glucocorticoid
Glucocorticoids
hospital
Hydroxychloroquine
Immunosuppression
immunosuppressive
immunosuppressive therapy
kidney transplant recipient
kidney transplant recipients
medication
Methylprednisolone
MMF
mycophenolate
mycophenolate mofetil
oseltamivir
Patient
Pneumonia
Population
Prednisone
reduction in
reflect
report
risk
tacrolimus
therapeutic
therapy
Transplant
transplantation
treated
Treatment
treatment regimen
treatment with methylprednisolone
Trough level
was reduced
with COVID-19
[DOI] 10.1016/j.transproceed.2020.10.051 PMC 바로가기 [Article Type] Case Reports
[DOI] 10.1016/j.transproceed.2020.10.051 PMC 바로가기 [Article Type] Case Reports
Clinical course of COVID-19 disease in immunosuppressed renal transplant patients
Article
[키워드] acute rejection
Admission
age
biochemical parameter
clinical
clinical setting
complications
Course
COVID-19
COVID-19 disease
Dexamethasone
died
discharge
discharged
dosage
duration of hospitalization
effective
Follow-up
high risk
hospital
Hospitalization
identify
Immunosuppressed
Immunosuppression
immunosuppressive
information
inhibitor
Inpatient
Kidney injury
kidney transplant
Kidney transplantation
Laboratory
male
material
Methylprednisolone
Mortality
no significant difference
Patient
patients
patients with COVID-19
reduced
reducing
reduction
rehospitalization
rejection
renal
Result
Retrospective study
Safe
SARS-CoV-2
Severity of disease
Treatment
were recorded
withdrawn
[DOI] 10.3906/sag-2007-260 PMC 바로가기 [Article Type] Article
[DOI] 10.3906/sag-2007-260 PMC 바로가기 [Article Type] Article
The Management of Immunosuppression in Kidney Transplant Recipients with COVID-19 Disease: An Update and Systematic Review of the Literature
Review
[키워드] acute respiratory syndrome
adopted
affected
allograft outcomes
antiviral drugs
approach
article
Asymptomatic
asymptomatic patient
clinical condition
clinical conditions
complications
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-1
COVID-19
COVID-19 infections
COVID-19 patient
COVID-19-related complication
drug
immune system
Immunosuppression
immunosuppressive
Interaction
Invasive mechanical ventilation
kidney transplant
Kidney transplantation
literature
literature review
majority
management
material
mild COVID-19 symptoms
mTOR inhibitor
overall mortality
pandemic
Patient
patient outcomes
patients died
performed
PROTECT
recipient
recipients
rejection
remained
renal function
review
risk
SARS-CoV-2
SARS-COV-2 infection
severe acute respiratory syndrome coronavirus 2
symptomatic
symptomatic patient
the cytokine storm
the patient
therapy
Transplant
was used
with COVID-19
Withdrawal
worsening
[DOI] 10.3390/medicina57050435 PMC 바로가기 [Article Type] Review
[DOI] 10.3390/medicina57050435 PMC 바로가기 [Article Type] Review
Computational Identification of Potential Anti-Inflammatory Natural Compounds Targeting the p38 Mitogen-Activated Protein Kinase (MAPK): Implications for COVID-19-Induced Cytokine Storm
Article
[키워드] Activation
aggregation
Anti-inflammatory
anti-inflammatory activity
anti-inflammatory compounds
Antiviral
AUC
AutoDock
binding energy
characteristic
China
Compound
Concentration
coronavirus
coronavirus disease
COVID-19
Critical
Cytokine storm
elevated
elicit
exhibit
exhibited
greater
identification
identify
immunosuppressive
in vitro
Inflammation
inhibitor
inhibitors
inhibitory
kinase
kinase inhibitors
MAPK
mitigate
molecular
molecular docking
Molecular dynamics simulation
natural
natural products
p38 MAPK
Patient
PDB ID
pharmacological
Platelet
platelet activation
Potential
predicted
pro-inflammatory cytokine
pro-inflammatory cytokines
profile
receptor
reported
residue
ROC
screened
storm
targeting
the cytokine storm
therapeutic target
Toxicity
with COVID-19
X-ray
[DOI] 10.3390/biom11050653 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/biom11050653 PMC 바로가기 [Article Type] Article
Repositioned Drugs for COVID-19—the Impact on Multiple Organs
Covid-19
[키워드] Anti-inflammatory effects
benefit
Central nervous system
Combination
Comorbidity
COVID-19
COVID-19 treatment
Critical
drug
drug repositioning
drug treatment
Effect
Efficacy
greater
heart
Hospitalization
immune system
immunosuppressive
Impact
kidney
kidneys
liver
Lungs
Multiple
Mutation
other organs
presence of comorbidity
protocols
public health
pulmonary system
Repurposed drug
severe COVID-19 symptom
supplementary material
treat
Vaccine
Vaccines
variant
virus
[DOI] 10.1007/s42399-021-00874-8 PMC 바로가기 [Article Type] Covid-19
[DOI] 10.1007/s42399-021-00874-8 PMC 바로가기 [Article Type] Covid-19
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial
SARS-CoV-2 백신(비활성화, Vero 세포)의 효능과 안전성을 평가하기 위한 무작위 이중 맹검 위약 대조 임상 3상 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
24 hour
24 hours
95% confidence interval
Activation
Active surveillance
administration
Administrative Personnel
Adverse
adverse event
adverse events
Adverse reaction
Adverse reactions
African green monkey
age
Algorithm
Aluminium
aluminium hydroxide
anaphylaxis
Antibody test
Antibody titer
Antigen
Arm
asplenia
assigned
assumed
assumption
Autoimmune
baseline
bleeding disorders
Blinding
blood product
blood products
blood sample
Blood samples
breastfeeding women
breath
carried
Cell culture
China
chloride
Clinical efficacy
clinical trial
code
Cohort
cohorts
comparator
consent form
cooperation
Corticosteroid
Corticosteroids
COVID-19
COVID-19 cases
COVID-19 disease
COVID-19 symptoms
COVID-19 test
criteria
Critical
CRO
Data and Safety Monitoring Board
Day
development
diary
dihydrogen
DIHYDROGEN PHOSPHATE
disease
disodium
disodium hydrogen phosphate
dissemination
dose
dose of vaccination
double blind
double-blind
double-blind study
Efficacy
Efficacy and safety
element
eligible
Endpoint
enrolled
enrolment
ethics committee
evaluate
event
excluded
exclusion criteria
expected
Follow-up
follow-up period
Frequency
Gender
genders
green monkey
group
groups
healthcare
Healthcare professional
healthcare professionals
higher risk
HIV infection
hospital
Hospitalization
hydrogen
Hydrogen phosphate
hydroxide
hypersensitivity
identity
IgG level
IgG levels
IgG test
immunogenicity
Immunoglobulin
immunoglobulins
immunosuppressive
immunosuppressive therapy
inactivated
Inactivated Vaccines
incidence
incidence rate
include
Inclusion
individual
information
informed consent form
initiated
Interactive Web Response System
intramuscular dose
investigator
IWRS
IWRS system
kidney
knowledge
Local
local reactions
management
medical doctors
medical emergency
Ministry of Health
mortality rates
neutralizing antibody
Neutralizing antibody titer
Novel coronavirus
number
Nurses
objective
Omega
Other
participant
PCR
PCR positivity
performed
Phase III Clinical Trial
phosphate
Placebo
placebo group
placebo-controlled
positive
pregnancy test
pregnant
preparation
primary efficacy endpoint
professional
proportion
protocol
randomised
randomised controlled trial
randomised placebo controlled trial
randomization
Randomized
Randomly
Reactions
receive
recorded
regimens
Registration
reported
response
risk
risk of infection
RT-PCR
RT-PCR test
RT-PCR tests
Safety Monitoring Board
Sample size
SARS-CoV-2 vaccine
SARS-CoV-2 virus
screened
second dose
secondary
Secondary objectives
Serious Adverse Event
Serious Adverse Events
seroconversion rate
Seropositivity
severity
severity of COVID-19
shown
Sinovac
sodium
Sodium chloride
sodium dihydrogen phosphate
Sponsor
status
study group
Study protocol
subject
subject’
supplementary material
Symptom
symptomatic
symptomatic case
symptomatic cases
System
systemic adverse reaction
the ethics committee
the timing
the vaccine
therapy
Treatment
treatment arm
Trial
Turkey
two-sided
vaccinated groups
vaccination
Vaccine
Vero
Vero Cell
Web
website
width
with COVID-19
within 6 months
[DOI] 10.1186/s13063-021-05180-1 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05180-1 PMC 바로가기 [Article Type] Letter
Cytomegalovirus proctitis as a complication of COVID-19 with immunosuppressive treatments
Case Report
[키워드] Anakinra
complication of COVID-19
Course
COVID-19
cytomegalovirus
Cytomegalovirus infections
Dexamethasone
iatrogenic
immune dysregulation
immunomodulators
Immunosuppression
immunosuppressive
Immunosuppressive treatment
Proctitis
Rectal diseases
risk
Severe COVID-19 pneumonia
treated
[DOI] 10.1016/j.idcr.2021.e01111 PMC 바로가기 [Article Type] Case Report
[DOI] 10.1016/j.idcr.2021.e01111 PMC 바로가기 [Article Type] Case Report
Attenuation of porcine deltacoronavirus disease severity by porcine reproductive and respiratory syndrome virus coinfection in a weaning pig model
Research Article
[키워드] attenuation
average
blocked
cause
caused
cells
cellular entry
Coinfection
cytokine
Cytokines
diarrhea
disease manifestation
disease severity
DPI
expressed
fecal
groups
IHC
IL-1
IL-6
immunosuppressive
indicated
inhibit
inoculated
Interaction
intestine
intestines
intranasally
lesion
less
macrophages
microenvironment
Neonatal
PAM
pathogen
Pathogenesis
pathogenicity
Porcine deltacoronavirus
porcine reproductive and respiratory syndrome virus
Proinflammatory cytokine
proinflammatory cytokines
proliferation
Regulation
Replication
reported
reproductive
risk
secreted
severity
supernatant
syndrome
TNF-α
virus
weaning
zoonotic
[DOI] 10.1080/21505594.2021.1908742 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1080/21505594.2021.1908742 PMC 바로가기 [Article Type] Research Article
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study
입원하지 않은 경증에서 중등도의 COVID-19 환자에서 장내 미생물군유전체 조절의 자연사 및 영향을 평가하기 위한 가상화된 임상 연구 장내 미생물군 구조에 대한 KB109의 생리학적 효과를 평가하는 병렬 그룹 연구와 함께 무작위, 공개, 전향적 연구 및 기능: 무작위 대조 연구를 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
24 hours
Ability
absence
addition
adhere
Affect
age
Ageusia
allergy
analysed
Anosmia
Anosmia/ageusia
Antacid
Antibiotics
Antiviral
assessment
assigned
Autoimmune disease
Bariatric surgery
baseline
bilevel positive airway pressure
Biomarker
Biomarkers
biomarkers of inflammation
BiPAP
Blinding
blocker
Blood
blood sample
Blood samples
both groups
bowel
bowel resection
breath
Care
care provider
Cell
change
Chest
chest tightness
chills
chronic lung disease
cirrhosis
clinical
clinical study
clinical trial
Cold
collected
Community
Comorbidity
comparator Patients
completion
Compliance
component
computer
Concomitant medication
concomitant medications
concurrent
condition
conducted
contraindications
coronavirus disease
Coronavirus disease 2019
cough
COVID-19
COVID-19 in patient
COVID-19 symptom
COVID-19 symptoms
COVID-19 testing
COVID-19-related symptom
COVID-19-related symptoms
COVID-19–related symptom
COVID-19–related symptoms
CPAP
Cytokines
D-dimer
daily dose
Day
defined
diarrhea
dissemination
drug
duration of symptom
Effect
element
eligible
Enrollment
evaluate
evaluate the effect
evaluated
exacerbated
exclusion criteria
exploratory
fatigue
fatty
Fatty acid
feasible
Female patients
Fever
fiber
Follow-up
follow-up period
following
group
Gut
gut microbiome
gut microbiome composition
gut microbiota
headache
Health
Health care
Health Care Utilization
Health status
healthcare
Histamine
history
hospital
Hospital admission
Hospital admissions
Hospitalization
Hospitalized
hypoxia
Identifier
IgM/IgG
Immunity
immunomodulatory
immunosuppressive
immunosuppressive therapy
in both group
include
Infection
Inflammation
Inflammatory biomarker
Inflammatory bowel disease
information
Informed consent
inhibitors
intake
Interaction
investigational agent
irritable bowel syndrome
KB109
Laboratory
laboratory measures
lactating
library
life
Liver disease
Lung disease
magnitude
malignancy
management
measure
Measures
medication
medications
Medicine
metabolite
Microbiome
microbiota
Mild
mild to moderate
Mild to moderate COVID-19
mild to moderate disease
moderate
Moderate COVID-19
moderate disease
modulate
modulation
muscle pain
nasal congestion
neutralization assays
not limited
nucleic acid
number
objective
Open-label
opinion
other compound
other compounds
outcome
outcome measure
Outpatient
outpatients
oxygen
oxygen saturation
Oxygen therapy
Pain
parallel group
participant
Participation
Patient
patient population
Period
Physical examination
positive airway pressure
Positive test
Potential
pre-symptomatic
pregnant
Primary outcome
progression
proportion
proportions
Prospective Study
PROTECT
protocol
protocols
proton pump
provided
pulse
Pulse oximeter
Quality of life
Quantitative
question
randomisation
randomised
randomised controlled study
randomization
Randomized
randomized controlled study
receive
recruitment
reduction
Registered
reported
response
resting position
risk
risk of infection
Sample size
screened
selected
self-care
sensitivities
Sequencing
serological
serology
shaking
short-chain fatty acids
Shortness of breath
Sleep
sleep apnea
Smartphone
sore throat
specific biomarker
specific biomarkers
Spread
SSC
Standard
Stool
stratified
Study design
Study protocol
study visit
supplementary material
Swab
Symptom
symptomatic patient
Symptomatic patients
Symptoms
syndrome
Tablet
TEAEs
Telemedicine
telephone
temperature
the patient
The United States
therapy
time
Tolerability
Treatment
treatment-emergent adverse event
undergo
United States
unlikely
Viral
Viral load
water
website
worsening
[DOI] 10.1186/s13063-021-05157-0 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05157-0 PMC 바로가기 [Article Type] Letter